Failure of epoprostenol (prostacyclin, PGI2) to inhibit platelet aggregation and to prevent restenosis after coronary angioplasty: results of a randomised placebo controlled trial.
about
Novel approaches for the prevention of restenosis.Calmodulin-stimulated cyclic nucleotide phosphodiesterase (PDE1C) is induced in human arterial smooth muscle cells of the synthetic, proliferative phenotype.Agonist-induced long-term desensitization of the human prostacyclin receptor.Leukocyte/endothelium activation and interactions during femoral percutaneous transluminal angioplasty.Effects of the co-polymer surfactant, Pluronic F-68, on platelet aggregation in human whole blood.
P2860
Failure of epoprostenol (prostacyclin, PGI2) to inhibit platelet aggregation and to prevent restenosis after coronary angioplasty: results of a randomised placebo controlled trial.
description
1994 nî lūn-bûn
@nan
1994年の論文
@ja
1994年論文
@yue
1994年論文
@zh-hant
1994年論文
@zh-hk
1994年論文
@zh-mo
1994年論文
@zh-tw
1994年论文
@wuu
1994年论文
@zh
1994年论文
@zh-cn
name
Failure of epoprostenol (prost ...... ised placebo controlled trial.
@ast
Failure of epoprostenol (prost ...... ised placebo controlled trial.
@en
type
label
Failure of epoprostenol (prost ...... ised placebo controlled trial.
@ast
Failure of epoprostenol (prost ...... ised placebo controlled trial.
@en
prefLabel
Failure of epoprostenol (prost ...... ised placebo controlled trial.
@ast
Failure of epoprostenol (prost ...... ised placebo controlled trial.
@en
P2093
P2860
P356
P1476
Failure of epoprostenol (prost ...... ised placebo controlled trial.
@en
P2093
Gershlick AH
Rothman MT
Spriggins D
Syndercombe Court YD
P2860
P356
10.1136/HRT.71.1.7
P577
1994-01-01T00:00:00Z